This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Lipids and Lipid Disorders  • Randomized Controlled Trial  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Effects of a Potent and Selective PPAR- Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia

Two Randomized Controlled Trials

Steven E. Nissen, MD; Stephen J. Nicholls, MBBS, PhD; Kathy Wolski, MPH; Daniel C. Howey, MD; Ellen McErlean, RN, MSN; Ming-Dauh Wang, PhD; Elisa V. Gomez, MS; John M. Russo, MD

JAMA. 2007;297:1362-1373. Published online March 25, 2007 (doi:10.1001/jama.297.12.1362).

Context  Fibrates are weak agonists of peroxisome proliferator–activated receptor (PPAR-). No trials have reported effects of more potent and selective agents.

Objectives  To examine the safety and efficacy of LY518674, a PPAR- agonist.

Design, Setting, and Participants  Two multicenter, randomized, double-blind, placebo-controlled trials: 1 in patients with elevated triglycerides and low HDL-C (atherogenic dyslipidemia), the other in patients with elevated LDL-C (hypercholesterolemia). Between August 2005 and August 2006, the dyslipidemia study randomized 309 patients at US centers; the hypercholesterolemia study, 304 patients.

Interventions  Dyslipidemia study: placebo, fenofibrate (200 mg), or LY518674 (10, 25, 50, or 100 µg) for 12 weeks. Hypercholesterolemia study: placebo or atorvastatin (10 or 40 mg) for 4 weeks, then placebo or LY518674 (10 or 50 µg) for 12 more weeks.

Main Outcome Measures  Dyslipidemia study: percentage change in levels of HDL-C and triglycerides. Hypercholesterolemia study: percentage change in levels of LDL-C.

Results  Dyslipidemia study: LY518674 (25 µg) and fenofibrate increased HDL-C by 5.9 and 5.5 mg/dL (15.8% and 14.4%) (both P.001 vs placebo, P = .79 between treatments). Higher LY518674 doses yielded smaller increases. LY518674 decreased triglycerides by 97.3 to 114.5 mg/dL (34.9% to 41.7%) but was similar to fenofibrate. LY518674 produced a dose-dependent increase in LDL-C, reaching 20.4 mg/dL (19.5%) for the 100-µg dose vs 0.3 mg/dL (2.3%) for fenofibrate (P.01). Fenofibrate and LY518674 (50 µg and 100 µg) increased serum creatinine (P.001 vs placebo), with 38% and 37.3% of patients exceeding the normal range. Fenofibrate, but not LY518674, increased creatine phosphokinase (P = .004 vs placebo). Hypercholesterolemia study: LY518674 (10 µg or 50 µg) decreased LDL-C by 21.4 to 26.0 mg/dL (13.2%-15.8%) and triglycerides 37% for both doses, and increased HDL-C by 6.3 to 6.7 mg/dL (12.5%-15.0%). When added to atorvastatin, LY518674 changed HDL-C by –0.7 to 6.2 mg/dL (–0.6% to 11.9%) and significantly decreased triglycerides but had no additional effect on LDL-C.

Conclusions  In patients with dyslipidemia, LY518674 and fenofibrate decreased triglycerides and increased HDL-C but also increased serum creatinine. LY518674, but not fenofibrate, increased LDL-C. In those with hypercholesterolemia, LY518674 reduced triglycerides and increased HDL-C, but did not further reduce LDL-C in combination with atorvastatin. Fenofibrate and LY518674 both raised safety concerns.

Trial Registration  clinicaltrials.gov Identifiers: NCT00133380 and NCT00116519

Author Affiliations: Department of Cardiovascular Medicine, Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio (Drs Nissen and Nicholls and Mss Wolski and McErlean); Eli Lilly and Company, Indianapolis, Ind (Drs Howey and Wang and Ms Gomez); and Guilford Medical Associates and Moses Cone Health System, Greensboro, NC (Dr Russo).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults--Invited Commentary
Thompson and Gau
Arch Intern Med 2009;169:578-579.
FULL TEXT  

High-density lipoprotein: why all the fuss?
Mackness and Mackness
Ann Clin Biochem 2009;46:5-7.
ABSTRACT | FULL TEXT  

Potent and Selective PPAR-{alpha} Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic Syndrome
Millar et al.
Arterioscler. Thromb. Vasc. Bio. 2009;29:140-146.
ABSTRACT | FULL TEXT  

Novel Peroxisome Proliferator-Activated Receptor {alpha} Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist
Mukherjee et al.
J. Pharmacol. Exp. Ther. 2008;327:716-726.
ABSTRACT | FULL TEXT  

Time to rethink high-density lipoprotein?
Wild and Byrne
Heart 2008;94:692-694.
FULL TEXT  

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Careskey et al.
J. Lipid Res. 2008;49:394-398.
ABSTRACT | FULL TEXT  

Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy
Glaysher and Van Heyningen
British Journal of Diabetes & Vascular Disease 2007;7:295-297.
 

Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.
Tuzcu et al.
J Am Coll Cardiol 2007;50:C2-31.
FULL TEXT  

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT | FULL TEXT  

Evidently...
Lehman
Evid. Based Med. 2007;12:103-103.
FULL TEXT  

Another Novel HDL-Raising Therapy, Another Negative Trial
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT